Case of a Diffuse Large B-Cell Lymphoma Patient Treated with Traditional Korean Medicine Treatment

미만성 거대 B세포 림프종 환자의 한의약치료 증례보고

  • Kim, In Soo (Department of Internal Medicine, College of Korean Medicine, Dong Shin University) ;
  • Cheong, Min Sung (Department of Internal Medicine, College of Korean Medicine, Dong Shin University) ;
  • Oh, Hyun Seung (Department of Internal Medicine, College of Korean Medicine, Dong Shin University) ;
  • Lee, Young Su (Department of Internal Medicine, College of Korean Medicine, Dong Shin University)
  • 김인수 (동신대학교 광주한방병원 내과학교실) ;
  • 정민성 (동신대학교 광주한방병원 내과학교실) ;
  • 오현승 (동신대학교 광주한방병원 내과학교실) ;
  • 이영수 (동신대학교 광주한방병원 내과학교실)
  • Received : 2013.10.22
  • Accepted : 2014.03.18
  • Published : 2014.04.25

Abstract

This case report that the therapeutic effects of traditional Korean medicine(TKM) treatment on the tumor response in a diffuse large B-cell lymphoma(DLBL) patient. A patient was treated by acupuncture, pharmacopuncture, moxibustion, cupping and herbal medicine once a week at least for 12 months. we evaluated the grade of chief complaints and performed blood tests and sonography, abdominal CT periodically. After 1 month administration with TKM treatment, the symptoms of the patient vanished obviously. the size of inguinal lymphoma decreased gradually through 3 months. then from 3 to 10 months, the size of inguinal lymphoma remained as it is. TKM treatment was maintained continuously. in the abdomino-pelvic CT performed after 12 months, the patient didn't complain any symptom and the size of inguinal lymphoma decreased a little again. This case study supports that TKM treatments may have a efficacy in treating diffuse large B-cell lymphoma(DLBL) patients.

References

  1. The Non-Hodgkin's Lymphomal Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood, 89: 3909-3918, 1997.
  2. 한지숙, 고윤웅, 민유홍 외 30인. 한국의 악성림프종에 관한 통계적관찰. 대한혈액학회지, 30: 197-203, 1995.
  3. Smith, A., Howell, D., Patmore, R., Jack, A., Roman, E. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. British Journal of Cancer, 105(11):1684-1692, 2001.
  4. Smith, A., Howell, D., Patmore, R., Jack, A., Roman, E. Haematological Malignancy Research Network. British Journal of Haematology, 148(5):739-753, 2010. https://doi.org/10.1111/j.1365-2141.2009.08010.x
  5. Arnold S. Freeman, Jon, C. Aster Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma. 2012.
  6. Swerdlow, S.H., Campo, E., Harris, N.L., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Lyon, pp 233-237, 2008.
  7. Sehn, L.H., Berry, B., Chhanabhai, M., et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Blood, 109: 1857-1861, 2007. https://doi.org/10.1182/blood-2006-08-038257
  8. 김현정, 홍대식. 미만성 거대 B세포 림프종의 포괄적 고찰. Journal of Soonchunhyang Medical Science, 14(3):467-476, 2009.
  9. Giantonio, B.J., Forastiere, A.A., Comis, R.L. The role of the Eastern Cooperative Oncology Group in establishing standards of cancer care : over 50 years of progress through clinical research. Semin Oncol, 35(5):494-506, 2008. https://doi.org/10.1053/j.seminoncol.2008.07.004
  10. 박재갑, 박찬일, 김노경. 종양학(Oncology). 서울, 일조각, p 772, 2009.
  11. Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R.S., Kuppes, R., Dalla-Favera, R. Hypermutation of multiple protooncogenes in B-cell diffuse large-cell lymphomas. Nature, 412: 341-346, 2001. https://doi.org/10.1038/35085588
  12. Sweet, D.L., Gaeke, M.E., Golomb, H.M., Ferguson, D.L., Ultmann, J.E. Survival of patients with localized diffuse histiocytic lymphoma. Blood, 58: 1218-1223, 1981.
  13. Nissen, N.I., Ersboll, J., Hansen, H.S., Walbom-Jorgensen, S., Pedersen-Hjergaard, J., Hansen, M.M., Rygard, J.A. randomized study of radiotherapy alone compared with chemotherapy versus radiotherapy plus chemotherapy in stage I-II non0hodgkin's lymphomas. Cancer, 52: 1-7, 1980.
  14. Coiffier, B., Lepage, E., Briere, J., et al. CHOP chemotherapy plus rituximalb compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346: 235-242, 2002. https://doi.org/10.1056/NEJMoa011795
  15. Fisher, R.I., Gaynor, E.R., Dahlberg, S., et al. Comparison of a standard regimen(CHOP) with three intensive chemotherapy regiments for advanced non-Hodgkin's lymphoma. Nengl J Med, 328: 1002-1006, 1993. https://doi.org/10.1056/NEJM199304083281404
  16. Feugier, P., Van Hoof, A., Sebban, C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J clin Oncol, 23: 4117-4126, 2005. https://doi.org/10.1200/JCO.2005.09.131
  17. Pfeundschuh, M., Trumper, L., Kloess, M., et al. Two-weekly or 3-weekly CHOP cheomtherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104: 634-641, 2004. https://doi.org/10.1182/blood-2003-06-2095
  18. 홍성일. 인간 암세포주에 대한 건칠 추출물의 선택적 세포 독성효과. 가천대학교 박사학위. 2007.
  19. 김재용, 정은정, 원영선, 이주혜, 신동영, 서권일. 인체 대장암 세포주 SW480에서 재배 와송의 세포 사멸 유도 효과. 한국식품과학회지 44(3):317-323, 2012.
  20. 김진성, 윤상협, 류봉하, 류기원. 와송의 수종 암세포에 대한 항암작용 연구. 대한한방내과학회지, 26(2):333-340, 2005.
  21. 임좌빈. 와송(瓦松)이 암에 미치는 효능. 대한한의학회지 4(1) 1996.
  22. 윤경수, 김영철, 이장훈, 우홍정. 瓦松이 만성 골수성 백혈병 세포주(K562)에서 세포사멸에 미치는 영향. 대한한방내과학회지 27(1):166-177, 2006.
  23. 박승찬. Akt 활성억제 및 Caspase-3의 활성화를 통한 삼칠근 열수 추출물의 인간 폐암세포에서의 세포사멸 유도. 대전대학교 박사학위. 2009.
  24. Savage, K.J., Harris, N.L., Vose, J.M., ALK-ana-plastic large-cell lymphoma is clinically and im-munopheno-typically different from both ALK+ALCL and peripheral T-cell lymphoma, not other-wise specified: report form the International Peripheral T-cell Lymphoma Project. Blood, 111(12):5496-5504, 2008. https://doi.org/10.1182/blood-2008-01-134270
  25. 김시내, 채의수, 김종광, 문준호, 이수정, 김윤정, 이유진, 손상균. 미만성 거대 B세포 림프종 환자 치료 후 절대 림프구 수 감소율의 예후적 가치. 대한내과학회지 76(1):52-59, 2009.